[go: up one dir, main page]

MXPA03008582A - Agentes y metodos para tratamiento de cancer. - Google Patents

Agentes y metodos para tratamiento de cancer.

Info

Publication number
MXPA03008582A
MXPA03008582A MXPA03008582A MXPA03008582A MXPA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A
Authority
MX
Mexico
Prior art keywords
cancer
agents
treatment
methods
Prior art date
Application number
MXPA03008582A
Other languages
English (en)
Inventor
Karen Seibert
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA03008582A publication Critical patent/MXPA03008582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
MXPA03008582A 2001-03-23 2002-03-21 Agentes y metodos para tratamiento de cancer. MXPA03008582A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27851201P 2001-03-23 2001-03-23
US09/961,969 US7012098B2 (en) 2001-03-23 2001-09-24 Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
PCT/US2002/008938 WO2002076395A2 (en) 2001-03-23 2002-03-21 Agents and methods for treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA03008582A true MXPA03008582A (es) 2003-12-08

Family

ID=26959136

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008582A MXPA03008582A (es) 2001-03-23 2002-03-21 Agentes y metodos para tratamiento de cancer.

Country Status (8)

Country Link
US (1) US7012098B2 (es)
EP (1) EP1463495A4 (es)
JP (1) JP2005500259A (es)
AU (1) AU2002248693A2 (es)
CA (1) CA2441394A1 (es)
EA (1) EA200300934A1 (es)
MX (1) MXPA03008582A (es)
WO (1) WO2002076395A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538184A (en) * 2002-08-23 2008-02-29 Pharmacia Corp Crystalline solid form of (2S-5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid 1.5 hydrochloride
ES2282355T3 (es) * 2002-10-11 2007-10-16 Sentoclone Ab Inmunoterapia de cancer.
CA2912259C (en) 2005-05-27 2020-04-28 Mark H. Schoenfisch Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8101173B2 (en) * 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071388A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
CA2634169C (en) * 2005-12-21 2012-11-27 Sentoclone Ab Method for treating disseminated cancer
US7951365B2 (en) * 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
AU2009270434B2 (en) * 2008-07-18 2015-04-09 Sentoclone International Ab Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
WO2010044875A2 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
EP2488591A1 (en) * 2009-10-13 2012-08-22 Novan, Inc. Nitric oxide-releasing coatings
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
CN104892477A (zh) * 2015-06-15 2015-09-09 尚科生物医药（上海）有限公司 手性2-甲基半胱氨酸及其盐酸盐的制备方法
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668651A (en) 1985-09-05 1987-05-26 Union Carbide Corporation Transition metal complex catalyzed processes
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
CN1095710A (zh) 1992-11-27 1994-11-30 惠尔康基金会集团公司 酶抑制剂
AU5704594A (en) 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5474955A (en) 1993-08-06 1995-12-12 Micron Technology, Inc. Method for optimizing thermal budgets in fabricating semconductors
KR100342275B1 (ko) 1993-10-21 2002-12-05 지.디. 썰 엘엘씨 산화질소신타제저해제로서유용한아미디노유도체
DE69431194T2 (de) 1993-10-21 2002-12-12 G.D. Searle & Co., Chicago Amidino-derivate nützlich als no synthase-hemmer
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
EP0749418B1 (en) 1994-03-10 2000-08-30 G.D. Searle & Co. L-n6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
AU2190895A (en) 1994-03-24 1995-10-09 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
ATE191470T1 (de) * 1994-06-15 2000-04-15 Wellcome Found Enzymhemmer
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
EP0821674B1 (en) 1995-04-20 2003-08-06 G.D. SEARLE & CO. Cyclic amidino agents useful as nitric oxide synthase inhibitors
JPH11511741A (ja) 1995-05-10 1999-10-12 ジー．ディー．サール アンド カンパニー 環状アミジン化合物から誘導される酸化窒素シンターゼインヒビター
US5830917A (en) 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
EP0892784A1 (en) 1996-04-13 1999-01-27 Astra Pharmaceuticals Limited Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
CA2322873A1 (en) 1998-03-11 1999-09-16 G.D. Searle & Co. Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
SE9802333D0 (sv) * 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
CN1279026C (zh) 1998-10-27 2006-10-11 艾博特公司 前列腺素内过氧化物h合酶生物合成抑制剂
AU1308400A (en) 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
AU2847200A (en) * 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
AU2661400A (en) * 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
US6403830B2 (en) * 2000-03-24 2002-06-11 Pharmacia Corporation Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
WO2002076395A3 (en) 2004-08-12
AU2002248693A2 (en) 2002-10-08
US20030013702A1 (en) 2003-01-16
WO2002076395A2 (en) 2002-10-03
EP1463495A2 (en) 2004-10-06
EP1463495A4 (en) 2005-11-16
US7012098B2 (en) 2006-03-14
EA200300934A1 (ru) 2004-12-30
CA2441394A1 (en) 2002-10-03
JP2005500259A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
AU6147401A (en) Compositions and methods for the treatment of cancer
GB2393202B (en) Methods of well treatment
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL159887A0 (en) Combination therapy for the treatment of cancer
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB2389532B (en) The method of treating cancer
MXPA03007036A (es) Metodo de terapia para cancer.
GB0124124D0 (en) Methods of treatment
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
ZA200203166B (en) Treatment of cancer.
GB0130763D0 (en) Treatment methods
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IL161630A0 (en) Methods of treating endometreosis
AU2002305138A1 (en) Methods and materials for cancer treatment
EP1303281A4 (en) METHODS OF TREATMENT
AU2002360454A8 (en) Methods and compositions for treating cancer
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
GB0115943D0 (en) Treatment and diagosis of cancer
GB0129451D0 (en) Treatment of cancer